WDFY3-AS2

ncRNA information

ncRNA name

WDFY3-AS2

Specific or universal ncRNAs

Specific ncRNAs

Class

Long noncoding RNA

Biomarker

None

Biomarker application

Upstream regulatory factors

Not available

Downstream target

hsa-miR-139-5p/SDC4

Cancer information

Cancer name

Ovarian Cancer

Cancer site

qRT-PCR,Western blot,Dual-luciferase assay

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis

Tissue resource

osteosarcoma tumor and paracancerous tissues

human osteosarcoma cell lines A2780

human cisplatin-resistant osteosarcoma cell lines A2780/DDP

Experiment

None


Institute

The First Affiliated Hospital of Anhui Medical University

American Type Culture Collection

Country

China

United States

Continent

Asia

North Amercian